Novartis’s Kymriah does not meet primary endpoint in phase III study
ZURICH, Aug 24 (Reuters) – Novartis ag (NOVN.S) said its Kymriah to treat aggressive B-cell non-Hodgkin lymphoma (NHL) after relapse or lack of response to first-line treatment did not meet its primary endpoint of event-free survival in a phase III study.
The safety profile was consistent with the established safety profile of Kymriah and Novartis will complete a full evaluation of the BELINDA study data, the Swiss drugmaker said in a statement on Tuesday.
